XXXX , an irreversible @entity470 family blocker, with protracted @entity2903 in recurrent @entity463 : a case report.

@entity1 @entity1313 @entity470 @entity12379 @entity71602 @entity2903 @entity463
UNASSIGNED: There are few effective treatments for recurrent @entity463 ( @entity463 ). We present a @entity1 with recurrent @entity463 who achieved a prolonged response to treatment with @entity12379 , an irreversible @entity470 family blocker, plus @entity2903 . A 58-year-old female @entity1 was diagnosed with multifocal primary @entity463 . After surgical resection, first-line therapy comprised radiotherapy and @entity2903 . Following disease progression after 3 @entity2903 cycles, the @entity1 entered a phase I/II clinical trial of @entity12379 (20-40 mg daily for 28 days) plus @entity2903 (50 mg/m2 every 21/28 days). Next-generation sequencing analysis of the @entity1313 specimen was performed. At the last assessment, 63 treatment cycles had been completed and the @entity1 had survived for ~5 years since recurrence. Significant disease regression was observed after 5 cycles and was maintained during long-term follow-up. Adverse events were consistent with the known tolerability profile of @entity12379 and were managed by treatment interruption/dose reduction. The @entity1 had several @entity470 ( @entity470 ) aberrations, including gene amplification and EGFRvIII positivity. Three somatic mutations were identified, including an unprecedented extracellular-domain substitution ( @entity71602 ). The @entity1 has survived ~6-fold longer than normally expected in @entity1 with recurrent @entity463 . The complex @entity470 genotype may underlie sustained response to @entity12379 plus @entity2903 .
